- Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
- Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
- Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
- Microbot Medical Shares Status Following Recent Geopolitical Events
- Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
- Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
- Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
- Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
- Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
- Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
More ▼
Key statistics
As of last trade, Microbot Medical Inc (CY9D:STU) traded at 1.71, 116.72% above the 52 week low of 0.7895 set on Apr 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.9055 |
---|---|
High | 1.90 |
Low | 0.904 |
Bid | 1.24 |
Offer | 1.28 |
Previous close | 0.912 |
Average volume | 488.89 |
---|---|
Shares outstanding | 14.40m |
Free float | 14.16m |
P/E (TTM) | -- |
Market cap | 14.40m USD |
EPS (TTM) | -0.8926 USD |
Data delayed at least 15 minutes, as of Jun 03 2024.
More ▼